Ophthalmology
Wet Macular Degeneration
13
Pipeline Programs↗
1
Active Trials↗
6
Companies Involved↗
Wet Macular Degeneration is an emerging landscape with 13 programs across 6 companies. The most active players are Chengdu Kanghong Biotech Co., Ltd., Roche, Pfizer. 4 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 11
Phase 3
No programs
Analysis
Modality Breakdown
13programs
Small molecule646%
Monoclonal antibody431%
Protein / enzyme215%
Peptide18%
Modality classified for 100% of 13 pipeline programs.
Analysis
Trial Status
4
clinical trials
Completed3 · 75%
Recruiting1 · 25%
Clinical Trials
Trial Activity
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
Completed·—·Phase 4·NCT01617148·26 enrolled
Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
Completed·—·Phase 1/2·NCT01926977·100 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)